The Week

Gossamer Bio (GOSS) surged 6020.94% this week to close at $10.73, while the S&P 500 fell 0.8%, leaving GOSS roughly 6021.74 percentage points ahead of the benchmark. The session path was uneven: Tuesday opened at $0.1715 and ended at $0.1799, Wednesday slipped to $0.1597, then Friday gapped up to $12.480, traded between $10.470 and $12.520, and settled at $10.730. The weekly amplitude came to 7212.89%, with heavy volume clustered on Wednesday and Friday, reflecting a violent repricing off an extremely low base.

Key Events

The week was dominated by seralutinib Phase 3 PROSERA data and the reverse stock split. On 8 September, the company highlighted PROSERA results and said it plans to file for a PAH new drug application. On 9 September, it announced a 1-for-80 reverse stock split and cut authorised shares to 50 million. On 11 September, the split took effect, and the same day GOSS hit a new 12-month low. The low is a direct consequence of the split’s re-pricing, not a comparable move on the old share base.

Analyst Ratings

Six brokers cover GOSS: two rate it buy, one overweight, and three hold, with no underweight or sell ratings. The consensus recommendation is buy, and the consensus target price of $165 sits about 1437.74% above the $10.73 spot. Target prices range from $80 to $320, a very wide spread. GOSS ranks 252nd out of 506 names in its biotech industry group.

The Week Ahead

Macro data comes thick and fast. The New York Fed manufacturing index lands on 15 September, with a prior of 20.6 and consensus 14.75. On 16 September, retail sales ex-autos, import prices, retail control, retail sales, the NAHB housing market index, and EIA crude inventory figures all arrive together. On the company side, the reverse split has just taken effect, so the market’s re-pricing of the new share range and liquidity will be worth watching, along with any follow-through on the PAH NDA filing after the PROSERA release.

In Short

GOSS re-priced violently this week on the combination of the reverse split and PROSERA data, leaving a wide gap between spot and broker targets. The consensus is buy and the target price sits well above spot, but targets stretch from $80 to $320, signalling deep disagreement. PB and PE are negative, and the latest session’s fund flow shows large and medium lots as net buyers while small lots lean the other way. The path ahead hinges on how the new share range trades after the split, the timing of the NDA filing, and next week’s macro batch.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.